Quick Answer
PALVELLA THERAPEUTICS, INC. reported Operating Income Loss of -$38.60 million for the year ending 2025.
- PALVELLA THERAPEUTICS, INC. showed a decrease of -173.9% in Operating Income Loss from 2024 to 2025.
- This data is from PALVELLA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2013 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2013 to 2025), PALVELLA THERAPEUTICS, INC.'s Operating Income Loss has declined by 14,088,221.2%.
- Historical annual values: Fiscal year 2025: -$38.60 million | Fiscal year 2024: -$14.10 million | Fiscal year 2023: -$11.87 million | Fiscal year 2022: -$43.47 million | Fiscal year 2021: -$51.83 million | Fiscal year 2020: -$33.92 million | Fiscal year 2019: -$27.16 million | Fiscal year 2018: -$30.83 million | Fiscal year 2017: -$14.59 million | Fiscal year 2016: -$22.76 million | Fiscal year 2015: -$13.68 million | Fiscal year 2014: -$7.20 million | Fiscal year 2014: -$15.7 thousand | Fiscal year 2013: $553.8 thousand | Fiscal year 2013: -$274.00.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: